Gene Panel Market Size
Gene Panel Market is valued at USD 3.33 billion in 2025 and is projected to reach USD 14.34 billion by 2035, growing at a CAGR of 15.72% during 2026–2035.
Precision diagnostics is becoming a strategic priority for laboratories, biotechnology companies, oncology centers, and research institutes as healthcare buyers seek faster, broader, and more clinically useful genetic testing.
Gene panels allow multiple genes to be analyzed in a single test, helping clinicians and researchers detect disease-associated mutations more efficiently than single-gene testing. In oncology, hereditary breast and ovarian cancer testing has moved beyond limited BRCA1 and BRCA2 analysis toward broader panels that can improve diagnostic yield and support personalized treatment decisions. This makes the market commercially relevant for diagnostic laboratories, sequencing platform providers, test kit manufacturers, hospitals, and biopharma companies working on companion diagnostics.
Key Takeaways
- The Gene Panel market size 2026 is recalculated at USD 3.85 billion, indicating a strong near-term opportunity for diagnostic laboratories and sequencing technology providers.
- The market is forecast to reach USD 14.34 billion by 2035, supported by a 15.72% CAGR and wider clinical use of multi-gene testing.
- North America holds the largest market share, driven by personalized medicine adoption, oncology testing demand, and strong presence of Gene Panel top companies.
- Asia-Pacific is the fastest-growing region as biotechnology capacity, clinical genomics adoption, and diagnostic infrastructure expand across major markets.
- Test kits are expected to remain a leading product category because laboratories need standardized, scalable, and workflow-ready panels for routine diagnostics.
- Genetic data privacy is a major adoption barrier because genomic information is permanent, highly sensitive, and difficult to remediate after a breach.
- Gene Panel pricing and adoption trends will be shaped by reimbursement readiness, laboratory automation, test interpretation tools, and the shift from single-gene testing to broader panel-based diagnostics.
Market Scope
| Metric | Details |
| Market Size in 2025 | USD 3.33 Billion |
| Market Size by 2035 | USD 14.34 Billion |
| CAGR | 15.72% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Product and Service, Technique, Design, Application, End-user, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
Gene Panel Growth Drivers and Adoption Barriers
Chronic Disease Burden Is Expanding the Use Case for Multi-Gene Testing
Gene panels are used in cancer risk assessment, syndrome-specific diagnostics, disease penetration studies, and treatment planning. The source content cites World Health Organization data indicating that chronic diseases were expected to contribute 73% of all deaths and 60% of the global disease burden in 2020, with 79% of these disease-related deaths occurring in developing countries. This disease burden supports demand for diagnostic tools that can identify genetic risk, support earlier clinical decisions, and guide personalized care.
Cancer, cardiovascular diseases, chronic obstructive pulmonary disease, and diabetes remain major areas where genetic information can support risk stratification, disease understanding, and therapeutic decision-making. As clinical pathways become more data-driven, gene panels are positioned as a practical bridge between broad genomic research and targeted diagnostics.
Multi-Gene Panels Offer Stronger Diagnostic Utility Than Narrow Testing
A key adoption driver is the ability of multi-gene panels to provide more information in a single test compared with limited BRCA1 and BRCA2 testing. For patients suspected of hereditary breast or ovarian cancer risk, broader panels can improve the chance of identifying clinically relevant variants beyond the two most widely recognized genes.
This creates a practical buyer benefit for hospitals and diagnostic laboratories. Broader panels can reduce the need for sequential testing, improve workflow efficiency, and support a more complete clinical report. For patients and physicians, the value lies in better-informed risk assessment and more targeted disease management.
Data Security Concerns Create a Serious Commercial Barrier
Genetic data is uniquely sensitive because it cannot be changed like passwords, financial credentials, or digital account information. A breach of genetic information can create long-term privacy risks for individuals and families. This makes data security a core procurement issue for laboratories, hospitals, and research organizations.
For vendors, cybersecurity, consent management, secure storage, compliant reporting, and data governance are becoming part of competitive differentiation. Buyers are likely to favor companies that can pair gene panel accuracy with strong data protection and transparent handling of genomic information.
Regulatory and Clinical Validation Requirements Shape Buyer Confidence
Regulatory readiness is an important market driver because gene panel results can influence clinical decisions. In vitro diagnostic kits, companion diagnostics, and oncology panels require robust validation, quality assurance, and clear clinical utility. The QIAGEN and Illumina partnership highlighted in the source content reflects the importance of expanding next-generation sequencing based in vitro diagnostic kits, including companion diagnostics for patient care management.
For buyers, regulatory credibility reduces adoption risk. For suppliers, validated workflows and clinically aligned panels can support premium positioning in hospital and laboratory procurement.
Market Opportunities
Diagnostic laboratories have a strong opportunity to expand from single-disease testing toward bundled multi-gene panel services in oncology, hereditary disease, pharmacogenomics, and rare disease testing. This is especially relevant where physicians need fast, interpretable, and clinically actionable results rather than raw sequencing data.
Technology providers can capture value through workflow automation, next-generation sequencing library preparation, variant interpretation, and artificial intelligence enabled reporting tools. The source content points to growing adoption of AI-enabled interpretation tools and bundled services in large diagnostic laboratories, particularly in oncology and pharmacogenomics.
For investors, the opportunity lies in a specialized B2B diagnostics niche with recurring testing demand, platform-based revenue potential, and strategic relevance to precision medicine. Companies with strong test menus, scalable laboratory workflows, and trusted data governance models are likely to be better positioned.
Substitute analysis also strengthens the case for gene panels. Single-gene testing may remain useful when a known mutation is being assessed, while whole exome or whole genome sequencing may be preferred for broader discovery applications. Gene panels occupy a commercially attractive middle ground because they are more targeted than genome-wide approaches and more informative than single-gene tests.
Gene Panel Market Segmentation Analysis
Segmented by Product and Service, by Technique, by Design, by Application, by End-user, and by Region - Share, Trends, and Forecast to 2035.
Product and Service: Test Kits Lead Laboratory Adoption
The test kits segment is expected to hold the largest share of the market. Demand is supported by research and diagnostic laboratories that need standardized tools to understand genetic variability in chronic disorders and hereditary conditions. Test kits reduce operational complexity for laboratories by providing defined workflows, known gene targets, and clearer compatibility with sequencing platforms.
Services are also important, particularly for laboratories and research institutes that require custom panel design, sequencing support, bioinformatics, and interpretation. As the market matures, bundled models combining kits, software, reporting, and technical support are expected to gain relevance.
Technique: Hybridization-Based Approaches Remain Important
The hybridization-based approach is expected to hold the largest share among techniques. The method has been refined over time to improve accuracy and reduce errors during the hybridization phase. Its relevance is tied to targeted sequencing workflows where laboratories need reliable capture of selected genes and disease-associated regions.
Thermo Fisher Scientific’s introduction of Ion AmpliSeq Hybridization-based technology in 2018 shows how library preparation innovation has supported next-generation sequencing adoption in targeted gene panels.
Application: Oncology and Hereditary Disease Testing Drive Practical Use Cases
Oncology remains one of the most commercially important applications because gene panels support cancer risk assessment, tumor profiling, hereditary cancer evaluation, and companion diagnostic development. BRCA1 and BRCA2 testing remains central to hereditary breast and ovarian cancer risk evaluation, but broader panels help identify additional mutations that may influence clinical decisions.
Practical use cases also include syndrome-specific diagnostics, rare disease evaluation, pharmacogenomics, disease penetration studies, and biomarker identification for research and drug development.
End-User: Laboratories, Biotechnology Companies, and Research Institutes Lead Demand
Diagnostic laboratories are key buyers because they translate gene panel technology into clinical testing services. Biotechnology companies use panels in biomarker discovery, drug development, and companion diagnostic programs. Research institutes rely on gene panels to investigate disease mechanisms, genetic variability, and targeted disease populations.
Gene Panel Regional Analysis
North America: Largest Market Share Supported by Personalized Medicine
North America holds the largest share of the global gene panel market. Demand is supported by advanced diagnostic laboratories, biotechnology companies, research institutes, cancer testing adoption, and increasing use of personalized medicine. The region also benefits from the presence of leading genomics companies and strong clinical interest in oncology-focused genetic testing.
Buyer demand in North America is shifting toward clinically validated, scalable, and secure testing workflows. Hospitals and laboratories are likely to prioritize turnaround time, reimbursement alignment, regulatory confidence, and data protection when selecting gene panel partners.
Europe: Clinical Quality and Data Governance Shape Adoption
Europe’s market outlook is influenced by advanced healthcare systems, genetic testing adoption, and strong emphasis on patient data protection. Laboratories in the region are likely to adopt gene panels where clinical utility is clear, especially in oncology, hereditary disease, and rare disease diagnostics.
Suppliers operating in Europe must compete on quality, compliance, clinical evidence, and interoperability with laboratory information systems. Genetic data protection remains especially important for buyer confidence.
Asia-Pacific: Fastest Growth Region With Expanding Genomics Capacity
Asia-Pacific is the fastest-growing region in the gene panel market. Growth is supported by expanding biotechnology capacity, rising diagnostic infrastructure, and growing adoption of advanced testing across China and other regional markets. Companies such as BGI and Novogene provide regional genomics strength, while international players continue to expand partnerships and service models.
Asia-Pacific also offers long-term opportunity in chronic disease testing and oncology diagnostics as healthcare systems increase investment in precision medicine and molecular testing.
Competitive Landscape and Company Product Mapping
The Gene Panel top companies include Illumina, Inc., Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI, Eurofins Scientific, Novogene Corporation, F. Hoffmann-La Roche AG, Integrated DNA Technologies, and Genewiz, Inc. Competition is shaped by sequencing platforms, panel design capability, laboratory workflow automation, in vitro diagnostic readiness, companion diagnostic partnerships, and interpretation support.
Illumina is positioned around sequencing and array technologies used in life sciences, oncology, reproductive health, agriculture, and molecular diagnostics. The company’s broad platform relevance supports its role in large-scale genetic variation analysis and molecular test development.
Thermo Fisher Scientific is active in targeted gene panel technology and next-generation sequencing workflow development. Its 2026 inherited disease panel launch in the source content highlights the direction of clinical laboratory automation and improved turnaround time.
QIAGEN is relevant through in vitro diagnostic kits, companion diagnostics, and partnerships. Its 15-year partnership with Illumina helped widen the availability and utilization of next-generation sequencing based in vitro diagnostic kits.
BGI and Novogene strengthen the market through genomics service capabilities and regional scale, particularly in Asia-Pacific. Eurofins Scientific and Genewiz support demand through testing and research services, while Agilent Technologies, Roche, and Integrated DNA Technologies contribute through tools, technologies, and life science product ecosystems.
Recent Developments
- May 2026 – Illumina, Inc. expands targeted sequencing solutions
Illumina enhanced its targeted sequencing portfolio by introducing advanced gene panel workflows with improved throughput, accuracy, and bioinformatics capabilities for oncology, inherited disease, and precision medicine applications. - May 2026 – Thermo Fisher Scientific Inc. strengthens clinical gene panel technologies
Thermo Fisher Scientific expanded its next-generation sequencing (NGS) solutions by introducing optimized targeted gene panels, automated library preparation, and enhanced data analysis tools for clinical diagnostics and translational research. - April 2026 – Agilent Technologies, Inc. advances targeted genomics portfolio
Agilent enhanced its target enrichment technologies and custom gene panel solutions to improve sequencing efficiency, biomarker discovery, and precision oncology research. - April 2026 – QIAGEN N.V. expands precision diagnostics workflow
QIAGEN strengthened its molecular diagnostics portfolio with improved sample preparation, targeted sequencing assays, and integrated bioinformatics platforms for clinical gene panel testing. - March 2026 – F. Hoffmann-La Roche Ltd. advances companion diagnostics development
Roche continued expanding its precision medicine portfolio by integrating targeted gene panel technologies into oncology diagnostics, biomarker identification, and personalized treatment selection. - March 2026 – BGI Genomics Co., Ltd. enhances high-throughput sequencing services
BGI expanded its targeted sequencing services with advanced gene panels supporting cancer genomics, reproductive health, rare disease diagnostics, and population-scale genomic research. - February 2026 – Eurofins Scientific SE strengthens genomic testing capabilities
Eurofins expanded its clinical genomics portfolio by enhancing targeted gene panel testing services for oncology, inherited disorders, and pharmacogenomics applications. - February 2026 – Integrated DNA Technologies, Inc. advances custom assay development
Integrated DNA Technologies expanded its portfolio of custom oligonucleotides, probes, and target enrichment solutions supporting highly accurate targeted sequencing workflows.
Report Benefits
This report helps diagnostic laboratories assess demand for test kits, sequencing workflows, interpretation tools, and service models. Biotechnology companies can use the analysis to evaluate biomarker discovery, companion diagnostic potential, and disease-specific panel opportunities. Investors can identify growth areas across precision diagnostics, oncology testing, rare disease panels, and laboratory automation. Suppliers can understand demand for reagents, sequencing technologies, library preparation tools, bioinformatics, and secure data infrastructure. Strategy teams can use the regional and competitive analysis to prioritize partnerships, market entry, and portfolio development.
Why Purchase the Report?
- Visualize the composition of the gene panel market segmentation by product & service, technique, design, application, end-user and region highlighting the key commercial assets and players.
- Identify commercial opportunities in gene panel market by analysing trends and co-development deals.
- Excel data sheet with thousands of data points of gene panel market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global gene panel market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience 2026
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
Target Audience:
- Diagnostic laboratories
- Biotechnology companies
- Pharmaceutical companies
- Genomics service providers
- Sequencing platform companies
- Hospitals and healthcare systems
- Oncology centers
- Research institutes
- Bioinformatics companies
- Investors in genomics and precision medicine sector
- Procurement teams
- Healthcare strategy teams
- Regulatory affairs teams
- Precision medicine program managers
